Incorporating genetic and clinical data into the prediction of thromboembolism risk in patients with lymphoma
Bastos, Mariana (Universidad Complutense de Madrid. Departamento de Biología Celular)
Ortiz, J. (Hospital General Universitario Gregorio Marañón)
Pradillo, V. (Hospital General Universitario Gregorio Marañón)
Salas, Eduardo (Gendiag. S.L. Scientific Department)
Marínez-Laperche, C. (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM))
Muñoz, A. (Hospital General Universitario Gregorio Marañón)
Buño, I. (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM))
Díez-Martín, José Luis (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM))
Soria Fernández, José Manuel (Institut d'Investigació Biomèdica Sant Pau)
Pascual Izquierdo, C. (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM))

Data:	2021
Resum:	Background: The incorporation of genetic variables into risk scores for predicting venous thromboembolic events (VTE) could improve their capacity to identify those patients for whom thromboprophylaxis would be most beneficial. Proof-of-concept of this is provided by the TiC-ONCO score for predicting the risk of VTE in patients with solid tumours. Our aim was to develop a similarly improved tool-the TiC-LYMPHO score-for predicting VTE in patients with lymphoma. Methods: In a retrospective observational study of 208 patients with lymphoma, 31 (14. 9%) were found to have experienced an episode of VTE either at the time of diagnosis or over the next 6 months. Clinical variables associated with VTE, determined via logistic regression analysis, plus the same genetic variables included in the TiC-ONCO score, were used to build the TiC-LYMPHO score algorithm. The sensitivity, specificity, predictive values and AUC of the TiC-LYMPHO, the Khorana and ThroLy scores were compared in the same population. Results: The TiC-LYMPHO score showed a significantly higher AUC, sensitivity and NPV (0. 783, 95. 35% and 97. 98% respectively) than the other scores. The ThroLy score showed a significantly higher specificity (96. 43% vs. 54. 49%; p < 0. 0001) and PPV (37. 50% vs. 26. 36%; p = 0. 0147) than the TiC-LYMPHO score, whereas its AUC, sensitivity and NPV were significantly lower (0. 579, 19. 35% and 86. 48%, respectively). Conclusion: These results show that by incorporating genetic and clinical data into VTE risk assessment, the TiC-LYMPHO score can categorize patients with lymphoma better in terms of their risk of VTE and allow individualized thromboprophylaxis to be prescribed.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Genetic risk score ; Lymphoma complications ; Thromboembolism risk
Publicat a:	Cancer Medicine, Vol. 10 Núm. 21 (november 2021) , p. 7585-7592, ISSN 2045-7634

DOI: 10.1002/cam4.4280
PMID: 34598309

8 p, 213.5 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats